Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
NRG Oncology
NRG Oncology
Eastern Cooperative Oncology Group
NRG Oncology
NRG Oncology
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
University of California, San Francisco
Mayo Clinic
Children's Oncology Group
National Cancer Institute (NCI)
Stanford University
University of California, San Francisco
Mayo Clinic
Children's Oncology Group
University of California, San Francisco
University of California, San Francisco
University of Michigan Rogel Cancer Center
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
NRG Oncology